Tehran University of Medical Sciences Journal of Pharmaceutical Care 2322-4630 12 2 2024 06 29 119 130 Jignesh Kansagra Department of Scientific and Medical Affairs, Sundyota Numandis Probioceuticals Pvt. Ltd., Gujarat, India Vishal Dubey Department of Scientific and Medical Affairs, Sundyota Numandis Probioceuticals Pvt. Ltd., Gujarat, India Dharmeshkumar Kheni Department of Scientific and Medical Affairs, Sundyota Numandis Probioceuticals Pvt. Ltd., Gujarat, India Varun Sureja Department of Scientific and Medical Affairs, Sundyota Numandis Probioceuticals Pvt. Ltd., Gujarat, India 2024 02 13 2024 04 02 Bone fracture is a common orthopedic condition that represents a significant health concern. Bone fracture repair process is a complex process that involves the harmonic and synchronized activity of bone cells. 5-lipoxygenase (5-LOX) is an enzyme responsible for the conversion of arachidonic acid to form leukotrienes. While leukotrienes have an empirical inflammatory role, various evidence suggests that these 5-LOX mediators, by switching the inflammatory environment and altering the activity of bone cells, have a detrimental effect on the bone fracture healing process. Additionally, various evidence suggests that 5-LOX inhibition shows improvement in the overall bone healing process and improves overall bone health. Despite this evidence, the clinical use of 5-LOX inhibitors in bone fracture healing is largely unexplored. The current review aimed to summarize the available evidence and pave the way for future large scale pre-clinical and clinical studies to evaluate the effectiveness of selective 5-LOX inhibitors in bone fracture healing. https://jpc.tums.ac.ir/index.php/jpc/article/view/653